The global HIV drugs market value was USD 32.1 billion in 2022, driven by the increasing prevalence of HIV across the globe. The market size is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to achieve a value of USD 47.8 billion by 2031.
The adoption of HIV drugs has been increasing steadily as the prevalence of HIV remains high, and advancements in antiretroviral therapy led to the development of more effective and tolerable treatments. The increasing focus on expanding access to treatment in low- and middle-income countries has further fuelled the growth of the market, as these regions account for a significant proportion of the global HIV burden.
HIV Drugs: Introduction
Human Immunodeficiency Virus (HIV) continues to be a significant global public health issue, affecting millions of people worldwide. HIV drugs, specifically antiretroviral therapy (ART), have played a crucial role in managing the disease and improving the quality of life for those living with HIV. ART involves the use of a combination of drugs that work together to suppress the virus, prevent its progression to Acquired Immune Deficiency Syndrome (AIDS), and reduce the risk of transmission.HIV Drugs Market Scenario
In recent years, the global HIV drugs market has witnessed considerable growth, driven by factors such as the increasing prevalence of HIV, advancements in antiretroviral therapy, the development of novel treatment regimens, and a growing focus on expanding access to treatment in low- and middle-income countries. The market is also fuelled by the rising demand for innovative therapies that offer improved efficacy, fewer side effects, and better patient adherence compared to traditional treatments.The adoption of HIV drugs has been increasing steadily as the prevalence of HIV remains high, and advancements in antiretroviral therapy led to the development of more effective and tolerable treatments. The increasing focus on expanding access to treatment in low- and middle-income countries has further fuelled the growth of the market, as these regions account for a significant proportion of the global HIV burden.
HIV Drugs Market Segmentations
Market Breakup by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Drugs
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors - CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Others
Market Breakup by Route of Administration
Oral
- Tablets
- Capsules
Parenteral
- Intravascular
- intramuscular
- Others
Market Breakup by Drug Type
- Branded
- Generics
Market Breakup by End User
- Hospitals
- Clinics
- Specialty Centers
- Research Institutes
- Others
Market Breakup by Distribution Channels
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the HIV Drugs Market
- New antiretroviral drugs and regimens: The development of novel antiretroviral drugs and treatment regimens has improved treatment outcomes and reduced side effects, leading to better patient adherence and overall quality of life
- Long-acting injectable therapies: The emergence of long-acting injectable HIV therapies has the potential to revolutionize treatment by reducing the burden of daily oral medication and improving treatment adherence
- Expanding access to treatment: Global efforts to increase access to antiretroviral therapy in low- and middle-income countries have contributed to the growth of the HIV drugs market
- Drug resistance and treatment optimization: Ongoing research focuses on addressing the issue of drug resistance, as well as optimizing treatment regimens to minimize side effects and maximize efficacy
- Prevention strategies: The market is also witnessing growth in the demand for pre-exposure prophylaxis (PrEP) drugs, which are used to prevent HIV infection in high-risk individuals
HIV Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- AstraZeneca
- GSK plc
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc
- Sun Pharmaceutical Industries Ltd
- Mylan N.V
- Sanofi
- Bayer AG
- ViiV Healthcare group of companies
- Genentech, Inc
Table of Contents
1 Preface
3 HIV/AIDS Overview
4 Patient Profile
5 HIV/AIDS Epidemiology Analysis
6 Global HIV Drugs Market Overview
7 Global HIV Drugs Market Landscape
9 Global HIV Drugs Market Dynamics
10 Global HIV Drugs Market Segmentation
11 North America HIV Drugs Market
12 Europe HIV Drugs Market
13 Asia Pacific HIV Drugs Market
14 Latin America HIV Drugs Market
15 Middle East and Africa HIV Drugs Market
16 Patent Analysis
17 Grants Analysis
18 Clinical Trials Analysis
19 Funding Analysis
20 Partnership and Collaborations Analysis
21 Regulatory Framework
22 Supplier Landscape
23 Global HIV Drugs Market-Distribution Model (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
26 Payment Methods (Additional Insight)
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Astrazeneca
- Gsk plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Mylan N.V.
- Sanofi
- Bayer AG
- Viiv Healthcare Group of Companies
- Genentech, Inc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | May 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 33.5 Billion |
| Forecasted Market Value ( USD | $ 47.8 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
